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Pregnant women with COVID-19 are at an increased risk of severe COVID-19 illness as well as 
adverse pregnancy and birth outcomes. Many countries are vaccinating or considering 
vaccinating pregnant women with limited available data about the safety of this strategy. Early 
identification of safety concerns of COVID-19 vaccines, including their components, or their 
technological platforms is therefore urgently needed. 
 
Methods 
We conducted a rapid systematic review, as the first phase of an ongoing full systematic review, 
to evaluate the safety of COVID-19 vaccines in pregnant women, including their components, 
and their technological platforms (whole virus, protein, viral vector or nucleic acid) used in other 
vaccines, following the Cochrane methods and the PRISMA statement for reporting 
(PROSPERO- CRD42021234185). 
We searched literature databases, COVID-19 and pregnancy registries from inception February 
2021 without time or language restriction and explored the reference lists of relevant systematic 
reviews retrieved. We selected studies of any methodological design that included at least 50 
pregnant women or pregnant animals exposed to the vaccines that were selected for review by 
the COVAX MIWG in August 2020 or their components or platforms included in the COVID-19 
vaccines, and evaluated adverse events during pregnancy and the neonatal period.  
Pairs of reviewers independently selected studies through the COVIDENCE web software and 
performed the data extraction through a previously piloted online extraction form. Discrepancies 
were resolved by consensus.  
 
Results 
We identified 6768 records, 256 potentially eligible studies were assessed by full-text, and 37 
clinical and non-clinical studies (38 reports, involving 2,397,715 pregnant women and 56 
pregnant animals) and 12 pregnancy registries were included.  
Most studies (89%) were conducted in high-income countries. The most frequent study design 
was cohort studies (n=21), followed by surveillance studies, randomized controlled trials, and 
registry analyses. Most studies (76%) allowed comparisons between vaccinated and 
unvaccinated pregnant women (n=25) or animals (n=3) and reported exposures during the three 
trimesters of pregnancy. 
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The most frequent exposure was to AS03 adjuvant in the context of A/H1N1 pandemic influenza 
vaccines (n=24), followed by aluminum-based adjuvants (n=11). Aluminum phosphate was used 
in Respiratory Syncytial Virus Fusion candidate vaccines (n=3) and Tdap vaccines (n=3). 
Different aluminum-based adjuvants were used in hepatitis vaccines. The replication-deficient 
simian adenovirus ChAdOx1 was used for a Rift Valley fever vaccine. Only one study reported 
exposure to messenger RNA (mRNA) COVID-19 vaccines that also used lipid nanoparticles. 
Except for one preliminary report about A/H1N1 influenza vaccination (adjuvant AS03) -
corrected by the authors in a more thorough analysis, all studies concluded that there were no 
safety concerns.  
 
Conclusion 
This rapid review found no evidence of pregnancy-associated safety concerns of COVID-19 
vaccines that were selected for review by the COVAX MIWG or of their components or 
platforms when used in other vaccines. However, the need for further data on several vaccine 
platforms and components is warranted given their novelty. Our findings support current WHO 
guidelines recommending that pregnant women may consider receiving COVID-19 vaccines, 
particularly if they are at high risk of exposure or have comorbidities that enhance the risk of 
severe disease. 
 





The COVID-19 Vaccines Global Access Facility (COVAX) is a multilateral initiative to ensure 
that all countries have fair and equitable access to Coronavirus Disease 2019 (COVID-19) 
vaccines. Co-led by the GAVI, the Vaccine Alliance, the Coalition for Epidemic Preparedness 
Innovations (CEPI), and the World Health Organization (WHO), COVAX is a voluntary 
arrangement that enables countries to pool their resources and risk by collectively investing in 
vaccine candidates while developing the political and logistical infrastructure needed for vaccine 
distribution in a transparent and coordinated manner[1-3]. Preauthorization clinical trials of 
COVID-19 vaccines excluded pregnant women, and only limited human data on their safety 
during pregnancy was available at the time of emergency use authorization[4]. However, 
pregnant women with COVID-19 are at increased risk of adverse pregnancy and birth outcomes 
and severe illness compared to non-pregnant women[5-9]. Many countries are vaccinating or 
considering vaccinating pregnant women especially if they are at risk of being exposed and even 
with limited available data about the safety of this strategy. Consequently, it is imperative to 
identify early safety concerns of COVID-19 vaccines, their components or their platforms; 
defined as any underlying technology -a mechanism, delivery method, or cell line- that can be 
used to develop multiple vaccines: whole virus, protein, viral vector, or nucleic acid. 
The main characteristics of the vaccines that were selected for review by the COVAX MIWG in 
August 2020 are presented in Table 1. To assist pregnant women, make a more fully informed 
decision, we aimed to identify safety concerns for pregnant women associated with these 
exposures through a rapid review of the literature databases as the first phase of an ongoing full 
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systematic review.  Given the urgency of the issue for current public health practice across the 
globe, we performed a rapid review as an interim analysis. 
Table 1 Main characteristics of the vaccines that were selected for review by the COVAX 





Construct Adjuvant Dose / Schedule 
Protein / 
subunit 




Stabilized Spike, △F 
Matrix-M™ Two doses at 5 µg 





trimeric Stabilized Spike 
AS03 5 µg + AS03 (0, 21 
days) 





Protein antigen SARS-CoV-2 Spike 





Two doses (0,28d) 
Clover  
Xiamen Innovax 
Biotech & GSK 
Recombinant 
protein vaccine 
S-protein trimer ASO3 / 
CpG1018 (in 
CHO cells) 
Two doses (0,21d) 
Vectored 






∆G-spike, (in MRC or Vero 
cells) 






Ad26; Stab. Spike; △F; TM 
No One dose at  5 × 1010 vp; 
2 doses at  5 × 1010 (0-
56) 




ChAdOx1 wild type Spike; 
TM 
No Two doses at 5 × 1010 







stabilized Spike, TM, FI 
No Two doses at 100 µg 
(0,28 days) 
BioNTech / Pfizer BNT162a b2 mRNA: encodes stabilized 
SARS-CoV-2 Spike 






No Two doses at 12 ug 
(0,28d) 
* Merck discontinued the development of this vaccine on January 25, 2021 
LNP: lipid nanoparticle; AS: Adjuvant System; CpG: Cytosine phosphoGuanosine; MRC: Human Fetal Lung Fibroblast Cells; CHO: 
Chinese hamster ovary; TM: transmembrane domain; S: Spike; FI: formalin-inactivated; rS: recombinant Spike 
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To evaluate the effects of COVID-19 the vaccines that were selected for review by the COVAX 




For this rapid review, we followed the Cochrane methods[10, 11] and the 2020 Preferred 
reporting items for systematic reviews and meta-analyses (PRISMA) statement[12] for reporting 
results. This review was registered in PROSPERO (CRD42021234185). 
 
Inclusion criteria  
We included studies that used comparative and non-comparative study designs. Case series were 
included only if they reported on more than 50 exposed pregnant women. We included also 
experimental studies of any size with exposed pregnant animals. We excluded systematic 
reviews (SRs) but explored their reference lists as an additional primary study source. 
The interventions or exposures of interest are the COVID-19 candidate vaccines that were 
selected for review by the COVAX MIWG in August 2020 or vaccine platforms 
(protein/subunit, vectored, nucleic acid/mRNA-LNP) or components (antigen, vehicle, construct, 
adjuvants, lipid nanoparticles or other components) used by COVID-19 vaccines. It was 
considered mandatory that at least one of these exposures was explicitly reported in the report. 
We considered outcomes concerning exposure to the vaccines based on the reported gestational 
age at vaccination (based on validated methods including ultrasound or last menstrual period 
[LMP] for human studies). We used the 21 standardized case definitions developed by the Global 
Alignment of Immunization Safety Assessment in Pregnancy (GAIA) of prioritized obstetric and 
neonatal outcomes based on the Brighton Collaboration process.[13] The ten GAIA obstetric 
outcomes include hypertensive disorders of pregnancy, maternal death, non-reassuring fetal 
status, pathways to preterm birth, postpartum hemorrhage, abortion/miscarriage, antenatal 
bleeding, gestational diabetes, dysfunctional labor, and fetal growth retardation. The 11 neonatal 
outcomes include congenital anomalies, neonatal death, neonatal infections, preterm birth, 
stillbirth, low birth weight, small for gestational age, neonatal encephalopathy, respiratory 
distress, failure to thrive and microcephaly.  
Safety outcomes were analyzed according to the US Food and Drug Administration (FDA) 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials.[14] An adverse event (AE) was defined as any untoward medical 
occurrence in a patient or clinical investigation subject administered a pharmaceutical product 
regardless of its causal relationship to the study treatment[15]. An AE can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of a medicinal (investigational) product. These 
include local reactions at the injection site (pain, tenderness, erythema, edema, pruritus, other) 
and systemic reactions (fever > 38oC or 100.4oF, headache, malaise, myalgia, fatigue, etc.). We 
also considered other post-vaccination medical events (unsolicited in the studies, reported by 
organ system as per Medical Dictionary for Regulatory Activities - MedDRA)[16]. 
We used the following classification to grade the severity of AEs: 
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  Mild (Grade 1): Events require minimal or no treatment and do not interfere with the subject’s 
daily activities. 
  Moderate (Grade 2): Events result in a low level of inconvenience or concern with therapeutic 
measures. Moderate events may cause some interference with functioning and daily activities. 
  Severe (Grade 3): Events interrupt the subject’s daily activities and may require systemic drug 
therapy or other treatment. Severe events are usually incapacitating. 
  Potentially Life Threatening (Grade 4): Potentially life-threatening symptoms causing 
inability to perform basic self-care functions with intervention indicated to prevent permanent 
impairment, persistent disability, or death. 
 
We also considered other classifications of AEs commonly reported in safety studies, including: 
-Medically attended adverse events (MAEs): events leading to an otherwise unscheduled visit to 
or from medical personnel for any reason, including visits to an accident and emergency 
department) 
-Serious adverse events (SAEs): resulted in death, were life-threatening, required hospitalization 
or prolongation of existing hospitalization, resulted in disability/incapacity, or a congenital 
anomaly/birth defect in the child of a study participant) 
-Adverse events of special interest (AESIs): events worthy closer follow-up over 6 months post-
vaccination. These include vaccine associated enhanced disease such as multisystem 
inflammatory syndrome (MIS-C/A). 
 
The operative definitions of each specific AEs were reported elsewhere (PROSPERO- 
CRD42021234185). For this rapid review we considered the integrative outcome “safety 
concerns” as any statistically significant adverse outcome reported in the comparative studies or 
unexpected figures, with respect to the published incidences in the peer-reviewed literature, 
reported in uncontrolled studies.  
 
Search strategy 
We searched published and unpublished studies without restrictions on language or publication 
status from inception to February 2021 (See Appendix 1) in the Cochrane Library databases, 
MEDLINE, EMBASE, Latin American and Caribbean Health Sciences Literature (LILACS), 
Science Citation Index Expanded (SCI-EXPANDED), China Network Knowledge Information 
(CNKI), WHO Database of publications on SARS CoV2, TOXLine, pre-print servers (ArXiv, 
BiorXiv, medRxiv, search.bioPreprint), and COVID-19 research websites (PregCOV-19LSR, 
Maternal and Child Health, Nutrition: John Hopkins Centre for Humanitarian health, the LOVE 
database). 
We also searched reference lists of relevant primary studies and systematic reviews retrieved by 
the search strategy, and adverse events/safety reported in active COVID-19 and pregnancy 
registries. Additionally, we reviewed information collected in COVID-19 and pregnancy 
registries. The Food and Drug Administration (FDA), the European Medicines Agency (EMA), 
clinical trials websites will be searched for the full review. We will then contact original authors 
and experts in the field for clarification or to obtain extra information. For the full review we will 
re-run the search strategy to capture any new evidence in databases between March 2021 and 
current date and time. 
Selection of studies, data extraction and assessment of risk of bias in included studies 
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Pairs of authors independently screened each identified record by title and abstract and retrieved 
all the full texts of the potentially eligible studies. Pairs of review authors independently 
examined the full text articles for compliance with the inclusion criteria and selected eligible 
studies. We resolved any disagreements by discussion. We documented the selection process 
with a 'PRISMA' flow chart[12]. This process was conducted through COVIDENCE,[17] a 
software for systematic reviews. 
Pairs of review authors independently extracted data from eligible studies using a data extraction 
form designed and pilot tested by the authors. We resolved any disagreements by discussion. 
Extracted data included study characteristics and outcome data. Where studies have multiple 
publications, we collated multiple reports of the same study under a single study ID with 
multiple references.  
In Appendix 2 we describe the risk of bias assessment tools used for each study design.  Briefly, 
we independently independently assessed the risk of bias of the included clinical trials using the 
Cochrane risk of bias assessment tool[18]. We used the Cochrane EPOC group tools[19] to 
assess controlled before after studies (CBAs), nationwide uncontrolled before after studies 
(UBAs), interrupted time series (ITSs); Controlled-ITSs (CITSs). We rated the risk of bias in 
each domain as “low”, “high”, or “unclear”. For observational cohort, case-control, cross-
sectional and case-series studies we used the NIH Quality Assessment Tool[20]. After answering 
the different signaling questions ‘Yes’, ‘No’, ‘Cannot determine’, ‘Not applicable’ or ‘Not 
reported’ the raters classified the study quality as “good”, “fair”, or “poor”. For consistency with 
the other designs, we use the classifications low, high or unclear risk of bias respectively. 
Data synthesis 
The primary analysis was the comparison of participants exposed and unexposed to the vaccines 
or their components. Data from non-comparative studies, including numerous registries, were 
collected and analyzed in the context of the expected global or country incidences of neonatal or 
obstetric outcomes. 
For dichotomous data, we used the numbers of events in the control and intervention groups of 
each study to calculate Risk Ratios (RRs), Hazard Ratios (HRs) or Mantel Haenszel Odds 
Ratios (ORs) or (for very rare events) Peto ORs. For continuous data, we calculated mean 
difference (MD) or standardized mean difference (SMD) between treatment groups depending 
on the use of the same or different scales, respectively. We treated large ordinal data as 
continuous data. We present 95% confidence intervals (CIs) for all outcomes. Where data to 
calculate RRs/ORs or MDs/SMDs were not available, we utilized the most detailed numerical 
data available that may facilitate similar analyses of included studies (e.g., test statistics, P 
values). We assessed whether the estimates calculated in the review for individual studies are 
compatible in each case with the estimates reported in the study publications. For randomized 
controlled trials (RCTs), we analyzed the data on an intention to treat basis as far as possible 
(i.e., including all randomized participants in analysis, in the groups to which they were 
randomized). For this rapid review we tabulated the study intervention/exposition characteristics 
and compared against the unexposed. We analyze the results of each study to determine any 
safety concerns as 'Yes', 'No' or 'Unclear'.  
 
We planned to conduct subgroup analyses by the trimester of exposure and sensitivity analysis 
restricted to studies with low risk of bias. However, these were not pursued for this rapid review 
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given the lack of safety concerns identified. We plan to perform meta-analysis and present 





We identified 6756 records, 265 potentially eligible studies were assessed by full-text and we 
included 37 clinical and non-clinical studies, involving 2,397,715 pregnant women and 56 
pregnant animals from 38 reports[4, 22-58]  (Fig 1).   
Description of studies   
 
The characteristics of included studies are described in Table 2. The most frequent study design 
was cohort studies (n=21) followed by surveillance studies (n=8), controlled trials (n=5) and 
registry analyses (n=3). Twenty-eight of the included studies (76%) allowed comparisons 
between vaccinated and unvaccinated pregnant women (n=25) or were conducted in animals 
(n=3). Nine out of the 37 studies (24%) were abstracts. 
The most frequent study location was the USA (n=6), followed by Sweden and United Kingdom 
(n=5 each), Australia, Canada, and Denmark (n=3 each), Cuba, France and Netherlands (n=2 
each), and Argentina, Belgium, Finland, Germany, Norway and multi country (n=1 each). Only 
4 out of 37 studies (11%) involved low-to-middle-income countries (LMICs)[27, 35, 44, 49]. 
Only 3 out of 37 studies were conducted in animals (8%)[28, 32, 57]. Most of the studies 
reported exposures during the three trimesters (n=17), only the first trimester (n=5), and the 
second and third trimester (n=4). In six studies the time of exposure was not reported. 
The most frequent exposures were to the AS03 adjuvant (536,240 pregnant participants from 23 
studies) and aluminum-based adjuvants (1,861,462 pregnant participants from 11 studies) (Table 
3). AS03 was the adjuvant of several A/H1N1 pandemic influenza vaccines (Pandemrix® and 
Arepanrix), while the influenza vaccine Equilis® used ISCOM-Matrix[32]. The aluminum 
phosphate was used in the testing of candidate Respiratory Syncytial Virus Fusion (RSV F) 
vaccines in pregnant women [28, 44, 48] (n=3). Aluminum phosphate was also used in Tdap 
vaccines[35, 45, 54] (n=3). Different aluminum salts were used in Hepatitis vaccines[23, 29, 36, 
46, 47]. One study reported on the use of the ChAdOx1 vector for a Rift Valley fever 
vaccine[57]. Only one study specific to COVID-19 was identified, reporting exposure to mRNA-
LNP from Pfizer & Moderna COVID-19 vaccines[4].  
The 12 COVID-19 and pregnancy registries identified (UKOS, PAN-COVID, BPSU, NPC-19, 
EPICENTRE, periCOVID, INTERCOVID, PregCOV-19LSR,PRIORITY, COVI-PREG), 
OTIS/MotherToBaby,CHOPAN, and vsafe registries) are presented in Table 4. The list of 
excluded studies and the reasons for exclusion is presented in Appendix 3.  
 
Risk of bias in included studies   
 
The risk of bias for the included controlled trials are presented in Table 5 and for the included 
observational studies in Table 6.  
We assessed the 38 included reports. Among the five RCTs two (40%) presented high risk of 
bias in the randomization process and one (20%) in blinding of participant and personnel. 
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Among the 33 observational study reports, 14 were classified as “good” (43%), 12 as “fair” 
(36%) and 7 as “poor” (21%). 
Outcomes of exposures 
The results of included studies are described in Table 2. There were 13 pregnancy-related 
outcomes (26 reports), 8 neonatal outcomes (19 reports) and 9 maternal outcomes (13 reports). 
The most reported pregnancy outcomes were preterm delivery (n=12), stillbirth (n=9), 
spontaneous abortion (n=9), fetal growth restriction/small gestational age (n=8), fetal death 
(n=6). The most reported neonatal outcomes were congenital anomalies (n=9), low birth weight 
(n=8) and the most reported maternal outcomes were local reactions (n=7), systemic reactions 
(n=5), serious adverse event (n=6).  
The adjusted relative effects comparing exposed vs. no exposed pregnant participants were 
summarized in Table 3. None of the available exposure, including AS03, aluminum phosphate 
or aluminum salts only, was statistically associated with adverse outcomes. Only AS03 showed a 
statistically lower frequency of very preterm aRR 0.73 (95%CI 0.58 to 0.91)[25] and peripartum 
complications aOR  0.65 (95%CI 0.42 to 0.99) [53]; and aluminum salts with lower stillbirth aHR 
0.49 (95%CI 0.29 to 0.84)[54]. The lack of more comparative information regarding “safety 
concerns” precludes further subgroup analysis by exposure. 
Of the 37 included studies, 36 (97%) concluded that there was no evidence of safety concerns. 
Only one study[55], reported as abstract, mentioned unclear safety concerns regarding the 9,026 
pregnancies ending in a delivery that had a record of the swine flu vaccine during or just before 
their pregnancy. The authors reported that they may not have captured early pregnancy losses 
and that some misclassification of outcome may have occurred or residual confounding after 
adjusting for age and chronic comorbidity may have been present. In fact the full-text manuscript 
reported one year later by these authors[56] included 9,445 women vaccinated before or during 
pregnancy and found no difference in the hazard of fetal loss during weeks 25 to 43 and a lower 
hazard of fetal loss than unvaccinated pregnancies in gestational weeks 9 to 12 and 13 to 24. 
The planned subgroup analyses by the trimester of exposure and sensitivity analysis restricted to 
studies with low risk of bias were conducted given the lack of reported safety concerns in every 
study.   
Table 4 shows the characteristics of the 12 identified COVID-19 and pregnancy registries, with 
potential data on safety/adverse events. The USA and the UK were the most represented 
countries. Some large registries are multinational, such as EPICENTRE, COVI-PREG or PAN-
COVID, which gathers data from 42 countries. Most registries include information on 
obstetric/pregnancy outcomes like early pregnancy loss, fetal growth, stillbirths, and delivery 
outcomes. All of them include neonatal and infant outcomes. Additionally, UKOSS and V-safe 
include specific vaccination information on the pregnant population. PeriCOVID was the only 
registry that collected blood samples. More detailed information on the relevant information 
from these registries will be described in the full systematic review, which is currently ongoing. 
 
We also identified three ongoing studies in the COVID-19 vaccine tracker developed by the 
Vaccine Centre at the London School of Hygiene and Tropical Medicine which contains 
information of the WHO, the Milken Institute and clinicaltrials.gov. databases[59]. One phase-2 
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trial is assessing the Ad26.COV2.S vaccine (a monovalent vaccine composed of a recombinant, 
replication-incompetent adenovirus type 26 vector)[60], and a phase-2/3 trial assessing the 
BNT162b2 vaccine (an RNA vaccine)[61] are being conducted in the United States, Australia, 
Brazil, Canada, Finland, South Africa, Spain, and in the United Kingdom. In addition, a phase-4 
nonrandomized controlled study is being conducted in Belgium to verify if Sars-Cov-2 specific 
antibodies can be demonstrated in blood serum and milk of lactating mothers vaccinated with the 
CX-024414 vaccine (mRNA vaccine)[62]. 
 


































    
                 *Two reports for the study Pasternak 2012 
 
Records identified from 
databases (n = 6756) 
Duplicate records removed 
before screening (n = 152) 
Records screened 
(n = 6604) 
Records excluded 
(n = 6351) 
Reports sought for retrieval 
(n = 253) 
Reports not retrieved 
(n = 0) 
Reports assessed for eligibility 
(n = 253) 
Reports excluded (n = 211) 
 
Wrong intervention     (n = 114) 
Insufficient information (n = 64) 
Wrong outcomes          (n = 17) 
Wrong population         (n = 10) 
Duplication                     (n = 4) 
Insufficient information   (n = 3) 
 
Awaiting classification (n = 4) 
 
Studies included in review 
(n = 37) 
Reports of included studies 
(n = 38)* 
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Table 2 Main characteristics and results of included studies     




names Exposure* Control 










2+3 Pandemrix AS03 No 
Intervention 
Stillbirth: aHR 1.05 (95% Confidence Interval [CI] 0.66–1.65) 
Early neonatal death: aHR 1.02 (0.43–2.40) 
Moderately preterm (28–36 weeks): aHR 1.00 (0.89–1.12) 
Very preterm (<28 weeks): aHR 0.90 (0.55–1.45) 
Moderately low birth weight (1500 g–2499 g): aHR 1.05 (0.90–1.21) 
Very low birth weight (<1500 g): aHR 0.84 (0.61–1.16) 
Fetal growth restriction: aHR 1.17 (0.98–1.40) 
The risk of adverse pregnancy outcomes was 
not associated with the exposure to the AS03 
adjuvanted pandemic influenza vaccine.  
 
No 










(Alum) / CpG 
1018 
No control Pregnancy-related adverse event (Havrix 64/378; Engerix-B 23/339; Twinrix 
103/199) 
Congenital anomalies/birth defects (Havrix 19/378; Engerix-B 29/339; Twinrix 
10/199) 
Major birth defects (Havrix 17/19; Engerix-B 20/29; Twinrix 7/10) 
Spontaneous abortions (Havrix 43; Engerix-B 57; Twinrix 26) 
No indication of any concerning pattern of 
adverse pregnancy outcomes following 











NR Pandemrix AS03 No control Fever and Flu-like symptoms: 37/56 (65.9%) 
Headaches: 9/56 (17.6%) 
Local reactions: 37/56 (65.9%) 
Congenital anomalies: 1/56 (1.4%) 
Exposure to the A(H1N1)v2009 pandemic 
influenza vaccine during pregnancy does not 
increase the risk of adverse pregnancy 
outcomes. 
No 






2+3 Pandemrix AS03 No 
Intervention 
Preterm birth (< 37 weeks): aRR (95% CI) 0.95 (0.88, 1.02) 
Very preterm birth (< 32 weeks): aRR 0.73 (0.58, 0.91) 
Small for gestational age: below 10th percentile: aRR 0.90 (0.85, 0.96) 
Small for gestational age: below 3rd percentile: aRR 0.81 (0.72, 0.92) 
5-minute Apgar score below 7: aRR 0.97 (0.82, 1.14) 
Fetal death: aRR 0.66 (0.47, 0.91) 
Second- or third-trimester H1N1 vaccination 
was associated with improved fetal and 









NR Pandemrix AS03 No control Uterine contractions: 2/12 
Spontaneous abortions: 4/12 
Stillbirth:1/12  
No strong signals of any unknown or serious 
adverse events associated with influenza 











1+2+3 Pandemrix AS03 No control Adverse effects 615/80,317 (0.8%) of the vaccinated pregnant women (fever 
32,4%;  
headache 30,3%; vomiting 12%; local reactions 9%; arthralgia 6,9%; 
dizziness 5%; allergic manifestations 3%; spontaneous abortions 0.3%; increase 
in uterine contractions 0.3%) 
No safety problem is associated to the 
Pandemrix vaccine. 
No 










Delivery rate Placebo: 80%; RSV F: 80% and RSV F  + AlP04: 90% 
3 stillbirths placebo vs  3 stillbirths in the adjuvanted RSV F group 
The RSV F vaccine was safe. The rates of 
pregnancy and stillbirth were similar between 
controls and vaccinees. 
No 











Not pregnant Vaccine-related fevers/chills: 25/77 (32%) (8/16 [50%] in non-pregnant women; 
p=0.25). 
Fetal growth restriction: 0/13; Preeclampsia/gestational hypertension: 0/13 
Preterm delivery: 1/13; Death: 0/13  
The cumulative symptom score after the 1st dose in all groups was low and after 
the 2nd dose, the cumulative symptom score (median (IQR) 2 (1-3), 3 (2-4), and 
2.5 (1-4.5) in pregnant, lactating, and non- pregnant groups respectively, p = 
0.40). 
There was no significant difference between 
pregnant, lactating, and non- pregnant groups 

























Gestational hypertension aOR (95%CI) 1.02 (0.80–1.30). 
Gestational diabetes: aOR 1.06 (0.91–1.23) 
Pre-eclampsia/eclampsia: aOR 1.07 (0.84–1.36) 
Cesarean delivery: aOR 1.01 (0.91–1.13) 
Pre-term birth (<37 weeks): aOR 1.14 (0.94–1.39) 
Low birth weight (<2500 g): aOR 1.21 (0.96–1.52) 
Small for gestational age at birth: aOR 1.13 (0.94–1.37)  
There were no significant associations 
between HepB exposure during pregnancy and 
maternal and neonatal outcomes. No 
increased risk for the adverse events that were 
observed among women or their offspring. 
 
No 






NR Arepanrix AS03 No 
Intervention 
Fetal loss: 7/550 (1.3%) vaccinees vs 11/325 (3.3%) unvaccinated, P=0.06 
Premature birth: 31/359 (8.6%) vaccinated vs 23/185 (12%) unvaccinated P=.21 
Of 261 vaccinees reporting weekly data, 11 (4.2%) reported an adverse event 
requiring missed work or an MD visit within 7 days of vaccination, most commonly 
acute respiratory illness (N=7). Only one event (arm numbness) was thought to 
be vaccine related. No serious adverse events were reported. 
Results to date suggest that pandemic 








2+3 Pandemrix AS03 No 
Intervention 
Fetal death HR IC95% 0.88 (0.66-1.17) 
Preterm delivery HR 1.00 (0.93-1.09) 
Low birth weight at term HR 0.90 (0.76-1.08) 
Low Apgar score at term   HR 1.08 (0.91-1.28) 
There is no evidence of association between 
vaccination and fetal death, preterm delivery, 





                
10  






Local reaction (swelling): 3/10 (in each dose) 
Pyrexia: 0/10 
Systemic reactions: 0/10 
The effects in the non-intervention was not reported 
The vaccine was shown to be safe in pregnant 
mares, foals and is used safely since 2 years 
as a commercial vaccine in Europe. 
No 
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studies women Intervention Early neonatal death: aHR 0.82 (0.46 to 1.49) 
Later death: aHR 0.78 (0.52 to 1.19)  
pregnancy does not affect the risk of stillbirth, 
early neonatal death, or later mortality in the 
offspring. 











Gestational diabetes aOR (IC95%) 0.94 (0.81–1.09) 
Pre-eclampsia:  aOR 0.99 (0.92–1.07) 
Stillbirth:  aOR 0.77 (0.57–1.03) 
Preterm birth: aOR 0.86 (0.77–0.96) 
Low birthweight: aOR 0.86 (0.77–0.96) 
Congenital malformations:  aOR 1.01 (0.83–1.23) 
Small-for-gestational-age:  aOR 1.04 (0.92–1.17) 
Vaccination during pregnancy with Pandemrix 














No control Adverse events following immunization (pregnant women): 1.46/100.000 
Adverse events following immunization vaccine 0.43/100.000 
Both vaccines presented a suitable safety 
profile. Since 2012 a downward trend in 
pertussis mortality was evident and no deaths 











1 Heplisav B  Aluminum 
phosphate / 
CpG1018 
Engerix-B Healthy term deliveries: 24 (60%) Heplisav-B  vs 11 (55%) Engerix-B  
Spontaneous abortions: 3 (7.5%) Heplisav-B vs 2 (10%) Engerix-B 
Congenital anomaly: 1 (2.5%) Heplisav-B vs 1 (5%) Engerix-B 
Stillbirths: 1 (2.5%) Heplisav-B vs 0 (0%) Engerix-B 
Heplisav-b shows similar fetal outcomes 








NR Pandemrix AS03 No control The French National Pharmacovigilance of A(H1N1) vaccination in pregnant 
women between October 2009 and March 2010, reported 13 intra-uterine deaths 
and12 spontaneous abortions. 
No causal relationship between immunization 
and in utero fetal death or spontaneous 




               
30,000  
Report Sweden Pregnant 
women 
1+2 Pandemrix AS03 No control Suspected adverse events: 50/30.000 (0.17%) 
Miscarriages: 31/30.000 (0.10%) 
Intrauterine fetal deaths: 7/30.000 (0.02%) 
The low number of reports with no defined risk 
profile would indicate that the vaccination with 
Pandemrix does not increase the risk for 










1+2+3 Pandemrix AS03 No control Miscarriages: 4/92 (4.3%) 
Congenital problems: 6/92 (6.5%) 
No safety conclusion 
 
No 






1+2+3 Pandemrix AS03 No 
Intervention 
Serious congenital malformation (1st trimester):  5.5% vs 4.5% unvaccinated   
Premature birth or low birth weight was also equally common in both groups, 
regardless of it time of vaccination. 
It appears to be safe even during the 









1+2+3 Pandemrix AS03 No 
Intervention 
Low birth weight <2,500 g: aOR (IC95%) 0.91 (0.79–1.04) 
Preterm birth <37 weeks: aOR 0.99 (0.89–1.10) 
Small for gestational age: aOR 0.97 (0.90–1.05) 
Low Apgar score at 5 min<7: aOR 1.05 (0.84–1.31) 
Caesarean section: aOR 0.94 (0.89-0.99) 
H1N1 AS03-adjuvanted vaccine during 
pregnancy, does not appear to adversely 
influence maternal or neonatal outcomes when 











1 Pandemrix  AS03 Siblings Congenital malformation: aOR (IC95%) 0.98 (0.89–1.07) 
Congenital heart disease: aOR 0.98 (0.84–1.15) 
Oral cleft: aOR 1.14 (0.67–1.94) 
Limb deficiency: aOR 0.90 (0.36–2.28) 
When intrafamilial factors were taken into 
consideration, H1N1 vaccination during 
pregnancy did not seem to be linked to overall 












1+2+3 Pandemrix AS03 No 
Intervention 
Miscarriages: 4/97 (4.1%) 
Potentially congenital abnormalities: 6/97 (6.2%) 
Stillbirths: 0/97 (0%) 


























Placebo Local injection-site reactions: 40.7% vs. 9.9% placebo; P<0.001 
Fever within 7 days: 1.2% vs 1.6% 
Systemic reaction: 41.2% vs 38.6% 
Serious adverse event: 29.8% vs 28.8% 
Any infant adverse event 82.3% vs 83% 
Serious adverse event: 44.3% vs 46.4% 
Serious adverse event with outcome of death: 0.6% vs 0.8% 
RSV F protein nanoparticle vaccination in 















Preterm birth (<37 weeks): aRR (95% CI) 0.99 (0.75–1.32) 
Low birth weight at term (<2500 g): aRR 1.19 (.61–1.11) 
Small for gestational age (<10th percentile): aRR 1.09 (.86–1.37) 
No significant associations were found 
between pertussis vaccination in pregnancy 
and adverse birth outcomes, regardless of the 
trimester of pregnancy. 
No 
















No control Pregnancy AEs: 41/139 (29.4%) 
Non-pregnancy specific outcomes:  21/139 (15.1%) 
Infant/neonatal outcomes:  12/139 (8.6%) 
No AE reported:  65/139 (46.8%) 
This review of VAERS reports did not identify 
any concerning pattern of AEs in pregnant 
women or their infants following maternal Hep 
A or Hep AB immunizations during pregnancy 
No 




1+2+3  Recombivax 
 Engerix-b,  
 Twinrix,  









No control Pregnancy-specific AEs:  61 (55.4%) 
Non-pregnancy specific AEs: 35 (31.8%) 
Infant outcomes: 22 (20.0%) 
Our analysis of VAERS reports involving 
hepatitis B vaccination during pregnancy did 



















Solicited AEs: 15/22 (68.2%) vs 10/28 (35.7%) 
Severe solicited AEs 0/22 vs 0/28 
The vaccine was well tolerated; no meaningful 
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Local solicited AEs  13/22 (59.1%) vs1/28 (3.6%) 
Systemic solicited AEs 6/22 (27.3%) vs10/28 (35.7%) 
Any unsolicited AE 22/22 (100.0%) vs 28/28 (100.0%) 
Severe unsolicited AE 3/22 (13.6%) vs 4/28  (14.3%) 
Severe & related unsolicited AE  0/22 vs 0/28 
Any medically attended AE  18/22 (81.8%) vs 25/28 (89.3%) 
Any serious AE (SAE) 3/22 (13.6%) vs1/28 (3.6%) 
were observed between study groups. 
Suggesting good tolerability of the RSV F 
vaccine among pregnant women and safety in 







1 Pandemrix AS03 No 
Intervention 
34/451 Vs  control group 21/205 (OR:0.71) for  some condition, minor or major. 
64,7% of findings in the vaccinated group were located in the kidneys (62,2% were 
renal ecstasy, either unilateral or bilateral)  
Vaccination against influenza virus A H1N1 did 
not increase the risk of birth defects when 
applied during the first trimester of gestation in 











1 Pandemrix AS03 No 
Intervention 
Systemic adverse reactions: 23/90 (25.6%) 
Local reactions: 64/90 (71.1%) 
Spontaneous abortions: 3/90 (3.3%) 
The results of our study do not indicate a risk 
for the pregnant woman and the developing 








1+2+3 Pandemrix AS03 Propensity 
score 
Major birth defects in gestational weeks 4 to 10: prevalence OR (POR) 1.24 (0.57-
2.71) 
Preterm birth: POR: 0.99 (0.84-1.17)  
Small size for gestational age: POR: 0.97 (0.86-1.09)  
Fetal death: HR (95%CI) 0.79 (0.53-1.16) 
Spontaneous abortion HR 1.11 (0.71-1.73) 
Stillbirth: HR 0.44 (0.20-0.94) 
Exposure to an adjuvanted influenza A(H1N1) 
pdm09 vaccine during pregnancy was not 
associated with a significantly increased risk of 
major birth defects, preterm birth, or fetal 
growth restriction. 
No 











Peripartum complications: 83/199 (41.7%) nonadjuvanted vs 127/509 (25.1%) 
adjuvanted (aOR 1.55; IC95% 1.01–2.39) 
The composite outcome of peripartum 
complications was more common in women 
who received the nonadjuvanted vaccine 
No 
Rega 2016[54] 5,155 Unclear Australia Pregnant 
women 




Local reaction. 7.1% Tdap and 3.2% TIV Active vaccine safety monitoring has not 
identified clinically significant issues. Pregnant 
woman vaccinated against influenza are less 

















Spontaneous loss adjusted for age and chronic comorbidity: aRR 1.54; CI95% 
1.36–1.74)  
We identified an increased miscarriage risk 
associated with influenza vaccination during 











1+2+3 Pandemrix AS03 No 
Intervention 
Fetal death 9 to 12 weeks unadjusted HR 0.56; CI95 0.43 to 0.73) 
Fetal death 13 to 24 weeks unadjusted HR 0.45; CI95 0.28 to 0.73)  
Fetal loss 9 to 12 weeks unadjusted HR 0.74; CI95 0.62 to 0.88)  
Fetal loss 13 to 24 weeks unadjusted HR 0.59; CI95 0.45 to 0.77) 
Influenza vaccination during pregnancy does 




                
16  
RCT  Netherlands Animals 2 ChAdOx1 
RVF 
Vectored Placebo All ewes and does in the ChAdOx1 RVF (n = 8) and mock-vaccinated groups (n = 
8) were in good health, with no clinical signs or other adverse events following 
vaccination 
When administered to pregnant sheep and 










1+2+3 Pandemrix AS03 No 
Intervention 
At least 1 MAE within the 31-daypost-vaccination: 59 (22.1 %) 
SAEs during the 181-day post-vaccination: 34 (12.7%) 
Observed / expected number of pregnancy outcomes by subgroup at vaccination: 
Spontaneous abortion: 4 (3.3%) (expected in the general population: 10–16%) 
Stillbirth :0 (expected in the general population: 0.51%) 
Congenital anomaly: 5 (1.9%) (expected in the general population: 2.09%) 
Preterm delivery (<37 weeks’ gestation): 14 (5.4%) (expected in the general 
population: 5.6%) 
Very pre-term delivery (<32 weeks’ gestation): 3 (1.1%) (expected in the general 
population: 1.7%) 
Low birth weight (<2.5 kg): 21 (8.1%) (expected in the general population: 7.1%) 
Very low birth weight (<1.5 kg): 4 (1.5%) (expected in the general population: 
1.2%) 
The results of this analysis suggest that 
exposure to the AS03 adjuvanted H1N1 (2009) 
vaccine during pregnancy does not increase 
the risk of adverse pregnancy outcomes 
including spontaneous abortion, congenital 
anomalies, preterm delivery, low birth weight 
neonates, or maternal complications. 
 
No 
* See adjuvants, platforms and constructs in table 1; # Argentina, Australia, Chile, Bangladesh, Mexico, New Zealand, the Philippines, South Africa, Spain, the United Kingdom, and the United States. 
A: Only available as abstract; RCT: Randomized Controlled Trial; aHR: adjusted Hazard Ratio; aRR: adjusted Relative Risk; aOR adjusted Odds Ratio; USA: United States of America; AE: Adverse Event; SAE: Serious AE; MAE: medically attended adverse event; 
RSV F: Respiratory Syncytial 
Virus Fusion 
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Table 3. Exposure to vaccine components/platforms 




Adjusted relative effects# $ 
(exposed vs no exposed) 
 
AS03[22, 24-27, 30, 31, 33, 34, 37-43, 49-53, 55, 56, 58] 536,240 23 (62%) Congenital malformation: 0.98 to 1.01 
Fetal death 0.66 to 0.88  
Early neonatal death: 0.82 to 1.02 
Later death: 0.78 
Preterm delivery 0.86 to 1.00 (Very preterm 0.73$ to 0.90) 
Low birth weight/small at term 0.86 to 1.04 
(<10th & 3rd percentile: 0.90 & 0.81; very low birth weight 0.84) 
Low Apgar score at term   0.97 to 1.08 
Gestational diabetes 0.94 
Pre-eclampsia:  0.99 
Stillbirth:  0.77 to1.05 
Caesarean section: 0.94 
Peripartum complications: 0.65$ 
 
*Aluminum phosphate[28, 35, 44, 45, 48] 1,852,842 5 (14%) Preterm birth: 0.99 
Low birth weight at term: 1.19 
Small for gestational age (<10th percentile): 1.09 
 
*Aluminum salts only[29, 46, 47, 54] 6,885 4 (11%) Stillbirth: 0.49$ 
Gestational hypertension 1.02 
Gestational diabetes: 1.06 
Pre-eclampsia/eclampsia: 1.07 
Cesarean delivery: 1.01 
Pre-term birth (<37 weeks): 1.14 
Low birth weight (<2500 g): 1.21 
Small for gestational age at birth: 1.13 
*CpG 1018 & Aluminum salts[23, 36] 1,735 2 (5%) Not available 
ISCOM-Matrix[32] 10 1 (3%) Not available  
mRNA-LNP[4] 84 1 (3%) Not available  
ChAdOx1 RVF[57] 16 1 (3%) Not available  
* Any aluminum exposure 1,861,462 pregnant participants from 11 studies; LNP: lipid nanoparticle 
# Adjusted Hazard Ratio; Relative Risk or Odds Ratio; $ statistically significant 
 
Table 4. COVID-19 and Pregnancy Registries 




Obstetric/pregnancy data Neonatal and infant outcome 
Samples 
collected 


























Pregnant w.  
COVID- 








UKOSS (National) UK No X X   X X X X X X X No X   
03/01/
20   X   
PAN-COVID (International) 42 countries Yes X X X X X X X X X   No X N/A N/A N/A N/A N/A 
BPSU (National) UK No   X       X X X X X No   N/A N/A       
NPC-19 (SONPM/AAP) 
(National) 
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periCOVID (International) 7 in Africa 
 7 in Europe 





America & Africa) 
Yes X X X X X X X X X X No X X 04/20/
20 





No X X X X X X X X X X No X X N/A N/A N/A N/A 
PRIORITY (National) USA Yes X X X X X X X X X X No X X 03/22/20 No No No 
COVI-PREG (International) 
23 countries in Asia, 
Africa, Europe, the 
Americas and 
Oceania 
Yes X X X X X X X X X X No X X N/A N/A N/A N/A 
OTIS/MotherToBaby (Multi-
national) 
North America (USA 
and 
 Canada) 
Yes X X X X X X X X X X No X X N/A N/A N/A N/A 
CHOPAN (Multi-national) Australia,  New Zealand No# X X X X X X X X X X No X No N/A       
vsafe pregnancy registry USA Yes X X X X X X X X X X No X X N/A   X X 
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Glenn 2015 Unclear Unclear Low Low Low Unclear Unclear 
Heldens 2009 High High Unclear Unclear Low Unclear High 
Madhi 2020 High High Unclear Unclear Low Unclear Unclear 
Muñoz 2019 Unclear Unclear High Low Low Unclear Unclear 
Stedman 2019 Unclear Unclear Unclear Unclear Low Unclear Unclear 
 
Table 5. Risk of bias of observational studies 
 Study ID Study design 
Signaling questions* 
Global Quality 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Baum 2015 Cohort studies Yes Yes Yes Yes No Yes Yes NA Yes No Yes No Yes Yes Good 
Galindo Santana 2011 Cohort studies Yes Yes Yes Yes No Yes Yes NA Yes No Yes No NR No Fair 
Gray 2021 Cohort studies Yes Yes Yes Yes No Yes Yes NA Yes NA Yes NR Yes No Fair 
Groom 2018 Cohort studies Yes Yes Yes Yes No Yes Yes NA Yes NA Yes NR Yes Yes Good 
Guo 2010 Cohort studies Yes CD CD CD CD Yes Yes NA CD NA CD NR Yes No Fair 
Jonas 2015 Cohort studies Yes Yes Yes Yes NR Yes Yes NA Yes NA Yes NR Yes Yes Good 
Källén 2012 Cohort studies Yes Yes Yes Yes NR Yes Yes NA Yes NA Yes NR Yes NR Fair 
Kushner 2020 Cohort studies Yes Yes Yes NR No Yes Yes No Yes Yes Yes NR NR No Fair 
Layton 2011 Cohort studies Yes CD CD CD CD Yes CD NA CD NA CD CD NR No Fair 
Levi 2012 Cohort studies Yes Yes CD CD CD Yes Yes NA CD NA CD CD NR CD Fair 
Ludvigsson 2013 Cohort studies Yes Yes Yes Yes NR Yes Yes NA Yes NA Yes NR No Yes Good 
Ludvigsson 2016 Cohort studies Yes Yes Yes Yes No Yes Yes NA Yes NA Yes NR Yes Yes Good 
Mackenzie 2012 Cohort studies Yes Yes Yes Yes NR Yes Yes NA Yes No Yes NR Yes No Fair 
McHugh 2019 Cohort studies Yes Yes Yes Yes No Yes Yes NA Yes NA Yes NR Yes Yes Good 
Núñez Rojas 2010 Cohort studies Yes Yes NR No No Yes Yes NA Yes NA No NR NR No Poor 
Oppermann 2012 Cohort studies Yes Yes Yes Yes Yes Yes Yes NA Yes NA Yes No Yes Yes Good 
Pasternak 2012 Cohort studies Yes Yes Yes Yes NR Yes Yes NA Yes No Yes NR Yes Yes Good 
Pasternak 2012 Cohort studies Yes Yes Yes Yes No Yes Yes NA Yes NA Yes NA NA Yes Good 
Ray 2014 Cohort studies No No CD Yes NR Yes CD NA No No No NR CD NR Poor 
Sammon 2011 Cohort studies Yes Yes Yes Yes No Yes CD NA Yes NA No NA NA No Poor 
Sammon 2012 Cohort studies Yes Yes Yes Yes No Yes Yes NA Yes No Yes No NR Yes Good 
Tavares 2011 Cohort studies Yes Yes CD Yes No Yes Yes NA Yes No Yes No No No Fair 
Fell 2012 Registry analysis Yes Yes Yes Yes No Yes Yes NA Yes NA Yes NA Yes Yes Good 
Haberg 2013 Registry analysis Yes Yes Yes Yes No Yes Yes NA Yes NA Yes NA No Yes Good 
Katz 2016 Registry analysis Yes Yes CD Yes No Yes CD NA Yes NA Yes NA NA NA Fair 
Celzo 2020 Surveillance Yes Yes CD No No Yes NR NR Yes NA Yes NA NA No Fair 
Chavant 2013 Surveillance Yes Yes NA Yes No Yes Yes Yes Yes No Yes No CD No Poor 
Folkenberg 2011 Surveillance Yes Yes CD Yes No Yes Yes NA Yes NA Yes NA NA NA Good 
Lacroix 2010 Surveillance Yes  Yes CD Yes No No Yes NA Yes No Yes NA NA No Fair 
Läkemedelsverket 2010 Surveillance Yes Yes CD CD No Yes Yes NA Yes NA No No NA No Poor 
Moro 2014 Surveillance Yes Yes CD Yes No Yes Yes NA Yes NA Yes NA NA NA Good 
Moro 2018 Surveillance Yes Yes NA Yes No Yes Yes NA No No Yes NA NA NA Poor 
Rega 2016 Surveillance No No Yes NR No Yes NR NA Yes NA NR NA NA No Poor 
 
NA: not applicable, NR: not reported, CD: cannot be determined 
*Signaling questions 
1. Was the research question or objective clearly stated in this study? 
2. Was the study population clearly specified and defined? 
3. Was the participation of eligible persons at least 50%? 
4. Were all subjects selected or recruited from the same or similar populations (including the same time frame)? Were the inclusion and exclusion criteria pre-
specified and applied to participate in the study of uniformly to all participants? 
5. Was a justification of the sample size, a description of the power, or estimates of variance provided and effect? 
6. For the analysis in this study, were the exposure (s) of interest measured before the outcome (s) were measured?  
7. Was the follow-up period long enough for one to reasonably expect to see an association between exposure and result if it exists? 
8. For exposures that can vary in quantity or level, did the study examine different levels of exposure in relation to with the outcome (for example, exposure 
categories or exposure measured as a continuous variable)? 
9. Were the exposure measures (independent variables) clearly defined, valid, reliable and implemented consistently across all study participants? 
10. Were the exposure (s) evaluated more than once over time? 
11. Were the outcome measures (dependent variables) clearly defined, valid, reliable and implemented consistently across all study participants? 
12. Were the outcome assessors blinded to the exposure status of the participants? 
13. Was the loss to follow-up after the start of the study 20% or less? 
14. Were potential key confounding variables statistically measured and adjusted for their impact on the relationship between exposure (s) and outcome (s)? 
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Through this rapid review, we found no evidence of safety concerns regarding the COVID-19 
vaccines that were selected for review by the COVAX MIWG in August 2020, their components or 
platforms used in other vaccines during pregnancy.  
None of the adjusted relative effects comparing exposed vs. no exposed pregnant participants of the 
available exposure results was statistically associated with adverse outcomes Only AS03 showed a 
statistically lower frequency of very preterm[25] and peripartum complications [53] and aluminum 
salts showed lower stillbirth aHR 0.49 (95%CI 0.29 to 0.84)[54]. Uncontrolled studies in general 
reported low frequencies of adverse outcomes. One study[55], reported as an abstract, suggested 
safety concerns regarding the swine flu vaccine (AS03 adjuvant) during or just before pregnancy, 
but the authors recognized potential bias for this finding. The authors published the full-text 
manuscript[56] one year later and after a more complete analysis they concluded that there is no 
evidence of safety concerns. 
Nine systematic reviews consistently supported the safety of influenza vaccines during 
pregnancy[63-71]. In general, cohort studies showed the benefits of vaccinating during pregnancy 
such as significantly decreased risks for preterm birth, small for gestational age and fetal death. 
However, after adjusting for season at the time of vaccination and countries' income level, only 
reduction of fetal death remained significant[67]. There is no evidence of an association between 
influenza vaccination and serious adverse events in the comparative studies[68]. When assessing 
only major malformations, no increased risk was detected after immunization at any trimester. 
Neither adjuvanted nor unadjuvanted vaccines were associated with an increased risk for congenital 
anomalies[70]. 
Other systematic reviews also assessed the safety of different vaccines. One SR evaluated the safety 
of hepatitis B, pneumococcal polysaccharide vaccine and meningococcal polysaccharide vaccines 
administration during pregnancy and found no clear association with a teratogenic effect on the 
fetus, preterm labor or spontaneous abortion[72]. Another SR evaluated safety of vaccines 
frequently given to travelers on pregnant women such as yellow fever, MMR (mumps, measles and 
rubella), influenza, Tdap (tetanus, diphtheria and pertussis), meningococcus or hepatitis A and 
B[73]. The authors concluded the safety of influenza vaccine is supported by high-quality evidence. 
For Tdap vaccine, no evidence of any unexpected harm was found in the meta-analysis of RCTs. 
Meningococcal vaccines are probably safe during pregnancy, as supported by RCTs comparing 
meningococcal vaccines to other vaccines. Data supported the safety of hepatitis A, hepatitis B 
vaccines during pregnancy. In summary primary and secondary evidence described supports the 
safety of COVID-19 vaccines, their components or their platforms used in other vaccines during 
pregnancy. 
Three recent studies about mRNA-LNP vaccines in pregnant women, published after this rapid 
review was finalized, reinforced these findings[74-76]. Shimabukuro el al, published preliminary 
results from the U.S. surveillance review of the safety of mRNA COVID-19 vaccines during 
pregnancy[75]. The solicited local and systemic reactions reported were similar among persons who 
identified as pregnant and non-pregnant women. Prabhu et al, studied the antibody response of 122 
pregnant women, and their neonates at time of birth,  who had received one or both doses of a 
mRNA-based COVID-19 vaccine[74]. COVID-19 vaccination in pregnancy induced a robust 
maternal immune response, with transplacental antibody transfer detectable as early as 16 days after 
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the first dose. Rottenstreich et al, 20 pregnant women who received two doses of SARS-CoV-2 
BNT162b2 (Pfizer/BioNTech) mRNA vaccine and found similar antibody response[76]. No safety 
concern was reported in any of these studies. Also, the proportions of adverse pregnancy and 
neonatal outcomes among completed pregnancies in the registry were similar to the published 
incidences in pregnant populations studies before the COVID-19 pandemic[77-83]. 
This rapid review has several strengths. First, we included reports without time, language, or 
publication type restriction, in human and animals, to provide a timely answer to a hot topic. 
Second, we adhered to rigorous recommended quality standards to conduct rapid reviews[11] 
including independent, data extraction and risk of bias assessment and a sensitive and 
comprehensive search strategy on literature databases to reduce the risk of missing relevant studies. 
Third, we categorized the exposition to the vaccine components and platforms, which was a 
challenging issue that demanded frequently to explore additional sources. Finally, we summarized 
and critically appraised a considerable amount of evidence to conclude if there are safety concerns 
of the components or platforms used by the vaccines that were selected for review by the COVAX 
MIWG in August 2020. The vaccines availability has changed over time[84] but we plan to update 
the search strategy covering the new vaccines for the ongoing full systematic review.  
Our study is not exempt from limitations. Only 11% of the total body of evidence comes from 
LMICs limiting the generalizability to these settings.  Additionally, only 76% of included studies 
allowed comparisons between vaccinated and unvaccinated pregnant women and only five of them 
were RCTs. Therefore, most of this evidence is observational. Nevertheless, the absence of safety 
concerns regardless the study design and publication type suggest that this could not be a major 
limitation. We are aware that the cut-off of 50 animals for non-human studies could be too high, but 
allowed us to provide timely answers through a rapid review in the context of the pandemics. 
Moreover, the set of non-controlled studies do not show unexpected figures with respect to the 
incidences published in the peer-reviewed literature of neonatal or obstetric outcomes[75]. 
Regardless of the exposure, all reported a rates of spontaneous abortion in exposed pregnant women 
described in Table 2 are below the reported the highest global incidence of 31%, or  10% when 
considering only losses occurring in clinically recognized pregnancies[77]. Tavares 2011 reported a 
rate of congenital anomalies of 1.9%, in line with the reported rate in the general population of 
approximately 2 to 4% of livebirths[78-82]. Regarding fetal death, rates reported by 
Läkemedelsverket 2010 (0.2%) – in Sweden - are consistent with the reported rates of stillbirth for 
high income countries: approximately 3 deaths per 1000 live births)[85]. None of the included 
studies conducted in LMICs reported stillbirth rates, which has been reported to be higher than in 
HIC: approximately 21 deaths per 1000 live births in low income countries[85]. 
We are aware that the list of Tdap vaccines included our review is incomplete due to the focus of 
our research question. This vaccine contains aluminum phosphate as adjuvant, which is not used for 
the COVID-19 vaccines under study, like the alhydrogel adjuvant. Therefore,  our search strategy 
did not include the term “Tdap”. Nevertheless, any aluminum adjuvant retrieved by our search 
strategy was included and reported. 
The nature of this rapid review did not allow us to search in FDA, the EMA websites, clinical trials 
registers or to contact authors and experts in the field to obtain additional data. For the same reason 
we could not conduct a meta-analysis that are planned for the full review phase. Regarding COVID-
19 and pregnancy registries we identified 12 national or international databases with potentially 
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useful information on safety outcomes. These will be further inspected in the next phase of this 
work. 
Based on existing data, it seems that there are no evident safety risks of COVID-19 vaccines 
components, or the technological platforms used for pregnant women. It is reasonable to consider 
COVID-19 vaccination in pregnant women, because their higher risk of adverse outcomes. The next 
full review phase will add stronger evidence over this important public health issue.  
Future experimental data will be needed to assess the pregnancy-related maternal and neonatal 
COVID-19 vaccine safety. Good quality safety registries, ideally with active surveillance, would 
also provide an extremely useful evidence from the real-world data. 
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